Denali Therapeutics Inc Cash Flow-to-Debt Ratio
Denali Therapeutics Inc cash flow-to-debt ratio. Denali Therapeutics Inc (DNLI) has a Cash Flow-to-Debt Ratio of -0.30x as of June 2026, meaning its operating cash flow of $-97.00 Million could theoretically repay 0% of its total liabilities ($322.78 Million) in one year. Check cash flow quality index of Denali Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Denali Therapeutics Inc (2015–2025)
Cash flow-to-debt ratio of Denali Therapeutics Inc from 2015 to 2025. Historical debt coverage capacity for Denali Therapeutics Inc across 11 annual periods. Check cash flow reinvestment rate of Denali Therapeutics Inc to assess the company's total reinvestment commitment from operating cash flow.
Denali Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Denali Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Denali Therapeutics Inc. For the full cash flow conversion analysis, see Denali Therapeutics Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.15x | $-412.60 Million | $131.09 Million | ▼ -30.8% |
| 2024 | -2.41x | $-347.69 Million | $144.50 Million | ▲ +17.3% |
| 2023 | -2.91x | $-357.99 Million | $122.96 Million | ▼ -397.1% |
| 2022 | -0.59x | $-244.72 Million | $417.81 Million | ▼ -22.4% |
| 2021 | -0.48x | $-211.39 Million | $441.87 Million | ▼ -152.2% |
| 2020 | 0.92x | $416.15 Million | $453.75 Million | ▲ +195.8% |
| 2019 | -0.96x | $-151.58 Million | $158.34 Million | ▼ -319.9% |
| 2018 | 0.44x | $50.12 Million | $115.14 Million | ▲ +111.9% |
| 2017 | -3.66x | $-76.64 Million | $20.93 Million | ▲ +16.2% |
| 2016 | -4.37x | $-72.36 Million | $16.55 Million | ▼ -1419.8% |
| 2015 | -0.29x | $-15.05 Million | $52.32 Million | — |